Green Cross Corporation operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Green Cross with three other
companies in this sector in South Korea:
sales of 982.07 billion Korean Won [US$863.24 million]
of which 88%
was Bio Business Division),
Samsung Biologics Co Ltd
(535.81 billion Korean Won [US$470.97 million]
of which 99%
was Finished Goods Revenues), and
Celltrion HealthCare Co Ltd
(713.49 billion Korean Won [US$627.16 million]
of which 96%
was Goods Sales).
Green Cross reported sales of 1.33 trillion Korean Won (US$1.17 billion)
December of 2018.
increase of 3.6%
versus 2017, when the company's sales were 1.29 trillion Korean Won.
Sales at Green Cross have increased during each of the previous five years
(and since 2013, sales have increased a total of 50%).
Sales of Greencross Genome saw an increase
that was more than double the company's growth rate: sales were up
32.4% in 2018, from
7.40 billion Korean Won to 9.79 billion Korean Won.
Green Cross also saw significant increases in sales in
Greencross Gclabcell (up 10.5% to 50.62 billion Korean Won)
Invacfarm (up 25.7% to 18.54 billion Korean Won)
Not all segments of Green Cross experienced an increase in sales in 2018:
sales of Greencross Ms fell 12.0% to 86.32 billion Korean Won.